Atea anticipates top line Phase III HCV results midyear 2026 while advancing HEV program (NASDAQ:AVIR)
Atea Pharmaceuticals(US:AVIR) Seeking Alpha·2026-03-05 23:57Management View - Atea Pharmaceuticals, Inc. reported significant clinical advancements in its global Phase III program for bemnifosbuvir and ruzasvir targeting HCV infections [2] - The CEO emphasized the rigorous execution of two pivotal Phase III trials, indicating strong progress in the company's drug development efforts [2]